The reproductive potential of young men and women with Hodgkin's disease.
D000328:Adult; D000568:Amenorrhea / Q000209:etiology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000013:Congenital Abnormalities / Q000209:etiology; D005260:Female; D005298:Fertility; D006689:Hodgkin Disease / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D007231:Infant, Newborn; D007247:Infertility, Female / Q000209:etiology; D007248:Infertility, Male / Q000209:etiology; D007989:Libido; D008297:Male; D008466:Mechlorethamine / Q000009:adverse effects; D008599:Menstruation Disturbances / Q000209:etiology; D009845:Oligospermia / Q000209:etiology; D010049:Ovarian Diseases / Q000209:etiology; D010053:Ovary / Q000503:physiopathology; D011241:Prednisone / Q000009:adverse effects; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic; D011344:Procarbazine / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects; D012306:Risk; D013737:Testis / Q000503:physiopathology; D014750:Vincristine / Q000009:adverse effects
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone